Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Pfizer, Washington U To Reposition Drugs
by Lisa M. Jarvis
May 24, 2010
| A version of this story appeared in
Volume 88, Issue 21
Pfizer will pay Washington University School of Medicine in St. Louis $22.5 million over five years to find new uses for current and old drug candidates. The drugmaker will provide detailed preclinical data on 500 molecules, giving the university a head start in finding potential new indications. As part of the pact, Pfizer’s indications discovery unit will move from the company’s Chesterfield, Mo., site to the Center of Research Technology & Entrepreneurial Exchange, which is adjacent to the medical school. The deal expands on a decades-long research relationship between Pfizer and the university.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X